The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...
Vertex Pharmaceuticals ( VRTX 5.31%) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic ...
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in the ...
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the ...
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...
(Reuters) -The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health ...
The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.